stoxline Quote Chart Rank Option Currency Glossary
  
FSD Pharma Inc. (HUGE)
0.0899  -0.01 (-10.1%)    08-14 16:00
Open: 0.095
High: 0.1042
Volume: 22,015,006
  
Pre. Close: 0.1
Low: 0.087
Market Cap: 0(M)
Technical analysis
2024-09-13 4:34:16 PM
Short term     
Mid term     
Targets 6-month :  17.22 1-year :  27.8
Resists First :  14.74 Second :  23.8
Pivot price 4.46
Supports First :  0.08 Second :  0.07
MAs MA(5) :  4.62 MA(20) :  5.08
MA(100) :  15.56 MA(250) :  44.93
MACD MACD :  -1.1 Signal :  -1.4
%K %D K(14,3) :  24.2 D(3) :  20.8
RSI RSI(14): 44.5
52-week High :  109.19 Low :  0.08
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ HUGE ] has closed below upper band by 48.3%. Bollinger Bands are 27.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.35 - 5.38 5.38 - 5.4
Low: 4.35 - 4.38 4.38 - 4.4
Close: 4.54 - 4.58 4.58 - 4.61
Company Description

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.

Headline News

Sun, 26 Jan 2025
FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc. - ACCESS Newswire

Mon, 25 Nov 2024
Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Allege - Newswire

Thu, 15 Aug 2024
FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM" - StockTitan

Mon, 12 Aug 2024
FSD Pharma Rebrands As Quantum BioPharma: Major Share Consolidation Announced - Benzinga

Mon, 12 Aug 2024
FSD Pharma changes its name to Quantum BioPharma - Green Market Report

Fri, 09 Aug 2024
FSD Pharma Backs Celly Nutrition’s Innovative Recovery Drink Launch - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 9.7 (%)
Held by Institutions 2.6 (%)
Shares Short 3 (K)
Shares Short P.Month 2 (K)
Stock Financials
EPS -16.25
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 17.09
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -36.5 %
Return on Equity (ttm) -63.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -14.4
Qtrly Earnings Growth 0 %
Operating Cash Flow -5 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -0.29
PEG Ratio 0
Price to Book value 0.26
Price to Sales 0
Price to Cash Flow -0.64
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android